已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer

杜瓦卢马布 医学 围手术期 化疗 膀胱癌 新辅助治疗 癌症 喉切除术 肿瘤科 泌尿科 内科学 外科 乳腺癌 喉 免疫疗法 无容量
作者
Thomas B. Powles,James W.F. Catto,Matthew D. Galsky,Hikmat A Al‐Ahmadie,Joshua J. Meeks,Hiroyuki Nishiyama,Toan Quang Vu,Lorenzo Antonuzzo,Paweł Wiechno,Vagif Atduev,Ariel Galapo Kann,Tae‐Hwan Kim,Cristina Suárez,Chao-Hsiang Chang,Florian Roghmann,Mustafa Özgüroğlu,Bernhard J. Eigl,Niara Oliveira,Tomáš Büchler,Moran Gadot
出处
期刊:The New England Journal of Medicine [Massachusetts Medical Society]
卷期号:391 (19): 1773-1786 被引量:494
标识
DOI:10.1056/nejmoa2408154
摘要

BACKGROUND: Neoadjuvant chemotherapy followed by radical cystectomy is the standard treatment for cisplatin-eligible patients with muscle-invasive bladder cancer. Adding perioperative immunotherapy may improve outcomes. METHODS: In this phase 3, open-label, randomized trial, we assigned, in a 1:1 ratio, cisplatin-eligible patients with muscle-invasive bladder cancer to receive neoadjuvant durvalumab plus gemcitabine-cisplatin every 3 weeks for four cycles, followed by radical cystectomy and adjuvant durvalumab every 4 weeks for eight cycles (durvalumab group), or to receive neoadjuvant gemcitabine-cisplatin followed by radical cystectomy alone (comparison group). Event-free survival was one of two primary end points. Overall survival was the key secondary end point. RESULTS: In total, 533 patients were assigned to the durvalumab group and 530 to the comparison group. The estimated event-free survival at 24 months was 67.8% (95% confidence interval [CI], 63.6 to 71.7) in the durvalumab group and 59.8% (95% CI, 55.4 to 64.0) in the comparison group (hazard ratio for progression, recurrence, not undergoing radical cystectomy, or death from any cause, 0.68; 95% CI, 0.56 to 0.82; P<0.001 by stratified log-rank test). The estimated overall survival at 24 months was 82.2% (95% CI, 78.7 to 85.2) in the durvalumab group and 75.2% (95% CI, 71.3 to 78.8) in the comparison group (hazard ratio for death, 0.75; 95% CI, 0.59 to 0.93; P = 0.01 by stratified log-rank test). Treatment-related adverse events of grade 3 or 4 in severity occurred in 40.6% of the patients in the durvalumab group and in 40.9% of those in the comparison group; treatment-related adverse events leading to death occurred in 0.6% in each group. Radical cystectomy was performed in 88.0% of the patients in the durvalumab group and in 83.2% of those in the comparison group. CONCLUSIONS: Perioperative durvalumab plus neoadjuvant chemotherapy led to significant improvements in event-free survival and overall survival as compared with neoadjuvant chemotherapy alone. (Funded by AstraZeneca; NIAGARA ClinicalTrials.gov number, NCT03732677; EudraCT number, 2018-001811-59.).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
2秒前
微山发布了新的文献求助10
3秒前
小贺y完成签到 ,获得积分10
3秒前
oaix完成签到 ,获得积分10
4秒前
5秒前
欢呼的糖豆完成签到,获得积分10
5秒前
可欣发布了新的文献求助10
6秒前
6秒前
熙熙攘攘完成签到,获得积分10
7秒前
7秒前
7秒前
7秒前
7秒前
VDC的应助被我看看怎么个事采纳,获得30
7秒前
7秒前
9秒前
9秒前
10秒前
墨苒发布了新的文献求助10
10秒前
RainlessYou完成签到,获得积分10
10秒前
11秒前
11秒前
12秒前
12秒前
13秒前
小蘑菇的应助被爱听歌的以山采纳,获得10
13秒前
yssmbf完成签到,获得积分10
13秒前
14秒前
14秒前
墨苒完成签到,获得积分10
14秒前
Ly完成签到 ,获得积分10
14秒前
FFFFcom完成签到,获得积分10
14秒前
CipherSage的应助被微山采纳,获得10
14秒前
吗喽完成签到 ,获得积分10
15秒前
daremo完成签到,获得积分10
15秒前
15秒前
15秒前
Beto发布了新的文献求助10
16秒前
16秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8184723
求助须知:如何正确求助?哪些是违规求助? 9573702
关于积分的说明 21832740
捐赠科研通 7782090
什么是DOI,文献DOI怎么找? 3434404
关于科研通互助平台的介绍 2558528
邀请新用户注册赠送积分活动 2481054